Chemotherapy News and Research

Latest Chemotherapy News and Research

Tumor-penetrating microparticles may offer treatment hope for those suffering with pancreatic cancer

Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein.

3 Nov 2009

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.

3 Nov 2009

Cuts in cancer care a move in the wrong direction of health care reform, says COA

The Community Oncology Alliance (COA) today criticized the newest round of cuts in cancer care as a move in the wrong direction of health care reform. Although not as devastating as expected, the cuts by the Centers for Medicare and Medicaid Services (CMS) will still decrease reimbursements far beyond what the U.S. cancer care delivery system, including most patients, can bear.

3 Nov 2009

IMC-RT does not benefit breast cancer patients

After mastectomy, breast cancer patients who receive radiation treatment to the lymph nodes located behind the breast bone do not live longer than those who do not receive radiation to this hard-to-treat area, according to a randomized 10-year study presented at the plenary session, November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

3 Nov 2009

Blue Cross Blue Shield of Michigan, OPR launch an innovative oncology treatment initiative

Blue Cross Blue Shield of Michigan and Oncology Physician Resource announced today the launch of an innovative oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.

2 Nov 2009

Bioengineers develop nano-delivery system for cancer therapy

Going smaller could bring better results, especially when it comes to cancer-fighting drugs.

2 Nov 2009

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

Solasia Pharma completes Phase I clinical trial for Sancuso extended release transdermal granisetron patch

Solasia Pharma K.K. (http://www.solasia.co.jp), a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today the completion of a Phase I clinical trial for SP-01 (extended release transdermal granisetron patch; brand name: Sancuso®) in Japanese volunteers.

30 Oct 2009

sanofi-aventis reports financial results for the third quarter of 2009

In the third quarter of 2009, sanofi-aventis generated net sales of euro 7,400 million, up 8.0% on a reported basis. Exchange rate movements had a favorable effect of 2.0 percentage points, with the appreciation of the U.S. dollar (and to a lesser extent the yen) against the euro more than offsetting the unfavorable effects of some other currencies.

30 Oct 2009

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.

30 Oct 2009

Eisai reports global Phase III study results of eribulin mesylate

Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

30 Oct 2009

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

TomoTherapy Incorporated announced today that several clinical presentations at the American Society for Radiation Oncology's 51st ASTRO Annual Meeting -- November 1-5, 2009 in Chicago -- will showcase the use of the TomoTherapy® radiation therapy platform as a vital component in the combined modality approach to treating cancer.

30 Oct 2009

AstraZeneca bolsters revenue with Toprol-XL and H1N1 vaccine sales

AstraZeneca, Third quarter revenue increased by 10 percent at constant exchange rates (CER) to $8,200 million.

29 Oct 2009

Positive results from Genta's Phase 3 trial of Genasense

Genta Incorporated today announced top-line results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense® in patients who have not previously received chemotherapy.

29 Oct 2009

NCCN Guidelines for breast cancer does not recommend prophylactic mastectomy in women

Despite a recent study finding that an increasing number of women who had cancer in one breast are opting to have the other breast removed, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology(TM) for Breast Cancer discourages prophylactic mastectomy in women except for those considered high risk.

29 Oct 2009

Treatment plan can benefit both doctor and patient

Jeff Gavin's diagnosis of leukemia last year threw him into a new world. Suddenly the father of five had to keep track of a bevy of new medicines and maintain a complicated series of appointments and hospital visits for chemotherapy.

29 Oct 2009

Recipients of the second round of funding under CLL/SLL Research Initiative announced by LRF

The Lymphoma Research Foundation (LRF) is pleased to announce that David Frank, MD, PhD of the Dana-Farber Cancer Institute and Thomas Kipps, MD, PhD, Moores Cancer Center, University of California, San Diego are the recipients of the second round of funding under the Foundation's Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Research Initiative.

29 Oct 2009

Nashboro Village Family Dental's initiative for childhood cancer

On Saturday, November 21, 2009 Nashboro Village Family Dental will present our First Annual Super Talent and All-Star Show. Hosted by Lelan Statom, WTVF, NewsChannel 5, this event will benefit Operation Stand Down and one of our patients that is battling chronic childhood cancer.

28 Oct 2009

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

28 Oct 2009

A.P. Pharma to transfer listing from The Nasdaq Global Market to The Nasdaq Capital Market

A.P. Pharma, a specialty pharmaceutical company, today announced that on October 26, 2009, the Company received notice that the Nasdaq Listing Qualifications Panel (Panel) has granted the Company’s request to transfer the listing of the Company’s common stock from The Nasdaq Global Market to The Nasdaq Capital Market, which will take effect with the opening of the market on Wednesday, October 28, 2009.

28 Oct 2009

Chemotherapy News and Research

Latest Chemotherapy News and Research

Tumor-penetrating microparticles may offer treatment hope for those suffering with pancreatic cancer

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Cuts in cancer care a move in the wrong direction of health care reform, says COA

IMC-RT does not benefit breast cancer patients

Blue Cross Blue Shield of Michigan, OPR launch an innovative oncology treatment initiative

Bioengineers develop nano-delivery system for cancer therapy

Amgen publishes Phase 3 study results of Aranesp

Solasia Pharma completes Phase I clinical trial for Sancuso extended release transdermal granisetron patch

sanofi-aventis reports financial results for the third quarter of 2009

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

Eisai reports global Phase III study results of eribulin mesylate

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

AstraZeneca bolsters revenue with Toprol-XL and H1N1 vaccine sales

Positive results from Genta's Phase 3 trial of Genasense

NCCN Guidelines for breast cancer does not recommend prophylactic mastectomy in women

Treatment plan can benefit both doctor and patient

Recipients of the second round of funding under CLL/SLL Research Initiative announced by LRF

Nashboro Village Family Dental's initiative for childhood cancer

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

A.P. Pharma to transfer listing from The Nasdaq Global Market to The Nasdaq Capital Market

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in